How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

"You have to be a really good student of the business and understand it inside and out and understand the industry," she told CNBC in an interview before her departure announcement. "Only when we understand the full system, can we navigate it well so that we bring value to it…That's my role as CFO." Eli Lilly's boom in revenue has allowed the company to invest heavily to scale up manufacturing, which will eventually get more medicine into patients' hands, Ashkenazi said. Ashkenazi, who will step in as the n ...